Abstract
Introduction
Asthenia is the most prevalent symptom in oncological patients but it is underestimated by the majority of healthcare professionals. The aim of the present study is to estimate the prevalence of tumour-related asthenia in the Spanish population, while defining the associated factors.
Methods
An epidemiological, multicentre, cross-sectional study was conducted in oncology services from Spain, including 712 cancer patients (58.4±13.5 years).
Results
42.5% patients showed asthenia. This prevalence appeared to be tumour-related (p<0.05) and increased among patients with a more advanced stage of disease or with a worsening of performance status (p<0.001). The prevalence of asthenia increased in the presence of the following factors: chemotherapy (in the past: 52.1% vs. 31.0%; at the time of the study: 46.1% vs. 38.2%), symptomatic treatment (in the past: 60.4% vs. 39.8%; at the time of the study: 61.3% vs. 38.6%), present interferon treatment (100%), anaemia (59.7% vs. 31.3%), dehydration/water-electrolyte imbalance (58.3% vs. 41.6%), respiratory failure (61.4% vs. 39.7%), liver disease (59.5% vs. 41.3%), malnutrition (76.1% vs. 38.7%), pain (57.7% vs. 27.0%), anxiety (56.1% vs. 38.6%), depression (57.9% vs. 40.0%) and sleep disturbances (51.1% vs. 39.4%). A multivariate logistic regression showed that a model including performance status, patient circumstance, chemotherapy, anaemia, pain and anxiety correctly diagnosed asthenia in 70.9% of cases.
Conclusions
The physiopathology of tumour-related asthenia remains relatively unknown, despite its high prevalence and considerable quality of life impact. Determining factors related to asthenia in clinical practice can favour the use of concrete treatments and improve the conditions of cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wagner LI, Janssen J, Mayordomo J (2006) Epoetin beta therapy in patients with solid tumours. Crit Rev Oncol Hematol 58:46–52
González Barón M, Camps C, Carulla J et al (2002) Estudio de la astenia tumoral: constitución del grupo ASTHENOS. Rev Clin Esp 202:525–528
Carulla J (2003) Astenia y eritropoyetina. V Congreso Nacional de la Sociedad Española de Cuidados Paleativos (SECPAL), 26–28 November, Las Palmas de Gran Canaria
World Health Organization (2007) International Statistical Classification of Diseases and Related Health Problems. 10th Revision. http://www.who.int/classifications/apps/icd/icd10online. Accessed 10 November 2007
Biswal BM, Kumaraswamy N, Mukhtar F (2004) Prevalence of fatigue among cancer patients undergoing external radiotherapy. Southeast Asian J Trop Med Public Health 35:463–467
Stasi R, Abriani L, Beccaglia P (2003) Cancer-related fatigue Evolving concepts in evaluation and treatment. Cancer 98:1786–1801
Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616–1634
Smets EM, Garssen B, Schuster-Uiterhoeve AL (1993) Fatigue in cancer patients. Br J Cancer 68: 220–224
Smets EM, Garssen B, Bonke B (1995) The multidimensional fatigue inventory (MFI): psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315–325
Sugawara Y, Akechi T, Okuyama T et al (2005) Occurrence of fatigue and associated factors in disease-free breast cancer patients without depression. Supportive Care Cancer 13:628–636
Bower JE, Ganz PA, Dickerson SS et al (2005) Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 30:92–100
Young KE, White CA (2006) The prevalence and moderators of fatigue in people who have been successfully treated for cancer. J Psychosom Res 60:29–38
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655
Reuter K, Classen CC, Roscoe JA et al (2006) Association of coping style, pain, age and depression with fatigue in women with primary breast cancer. Psychooncology 15:772–779
Pater JL, Zee B, Palmer M et al (1997) Fatigue in patients with cancer: results from the National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30. Support Care Cancer 5:410–413
Forlenza MJ, Hall P, Lichtenstein P et al (2005) Epidemiology of cancer-related fatigue in the Swedish twin registry. Cancer 104:2022–2031
Heinonen H, Violin L, Uutela A et al (2001) Gender-associated differences in the quality of life after allogeneic BMT. Bone Marrow Transplant 28:503–509
Redeker NS, Lev EL, Ruggiero J (2000) Insomnia, fatigue, anxiety, depression and quality of life of patients undergoing chemotherapy. Sch Inq Nurs Pract 14:275–290
Walsh D, Donnelly S, Rybichi L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 patients. Support Care Cancer 8:175–179
Hickok JT, Morrow GR, McDonald S, Bellg AJ (1996) Frequency and correlates of fatigue in lung patients receiving radiation therapy: implications for management. J Pain Symptom Manage 11:370–377
Blohmer JU, Dunst J, Harrison L et al (2005) Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 68:12–21
Pronzato P, Jassem J, Mayordomo J (2006) Epoetin beta therapy in patients with solid tumours. Crit Rev Oncol Hematol 58:46–52
Poirier P (2005) Policy implications of the relationship of sick leave benefits, individual characteristics, and fatigue to employment during radiation therapy for cancer. Policy Polit Nurs Pract 6:305–318
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
González Barón, M., Feyjóo, M., Carulla Torrent, J. et al. Study of the prevalence of tumour-related asthenia in Spanish cancer patients. Clin Transl Oncol 10, 351–358 (2008). https://doi.org/10.1007/s12094-008-0211-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-008-0211-z